Susan G. Komen
@susangkomen.bsky.social
Breast cancer research
Breast cancer care & financial support
Breast health advocacy & public policy
Breast cancer care & financial support
Breast health advocacy & public policy
Our “EmpowerED: Education After Diagnosis” event took place on Dec. 8, bringing together attendees for an evening of education, support and meaningful conversations, including a discussion about the power of asking for help and supporting one another.
https://bit.ly/48KDOUk
https://bit.ly/48KDOUk
December 23, 2025 at 5:54 PM
Our “EmpowerED: Education After Diagnosis” event took place on Dec. 8, bringing together attendees for an evening of education, support and meaningful conversations, including a discussion about the power of asking for help and supporting one another.
https://bit.ly/48KDOUk
https://bit.ly/48KDOUk
Update! FDA approves T-DXd (trastuzumab deruxtecan) combined with petuzumab for HER2+ metastatic breast cancer as 1st line treatment - backed by DESTINY-Breast09 clinical trial results.
Learn more here: https://bit.ly/4pIyc2V
Learn more here: https://bit.ly/4pIyc2V
December 18, 2025 at 3:51 PM
Update! FDA approves T-DXd (trastuzumab deruxtecan) combined with petuzumab for HER2+ metastatic breast cancer as 1st line treatment - backed by DESTINY-Breast09 clinical trial results.
Learn more here: https://bit.ly/4pIyc2V
Learn more here: https://bit.ly/4pIyc2V
"It's so important to always have advocates involved because it allows us to ask those questions to researchers like 'how will this help?'" - Komen patient advocate Bob Ritter shares his thoughts on all the research updates coming from @sabcs.bsky.social #SABCS
December 12, 2025 at 10:10 PM
"It's so important to always have advocates involved because it allows us to ask those questions to researchers like 'how will this help?'" - Komen patient advocate Bob Ritter shares his thoughts on all the research updates coming from @sabcs.bsky.social #SABCS
This week at #SABCS25, we presented pivotal work aimed at addressing needs within the #breastcancer community. Read more about the Komen-led research projects: https://bit.ly/4pyiJCe @sabcs.bsky.social
December 12, 2025 at 8:37 PM
This week at #SABCS25, we presented pivotal work aimed at addressing needs within the #breastcancer community. Read more about the Komen-led research projects: https://bit.ly/4pyiJCe @sabcs.bsky.social
🔬 We’re watching the science at #SABCS25. Komen Scholar Susan Domchek, M.D., is excited about the WISDOM trial using genetics & polygenic risk scores to personalize screening. @sabcs.bsky.social
📖 Read more: https://www.komen.org/blog/sabcs-watch-2025/
📖 Read more: https://www.komen.org/blog/sabcs-watch-2025/
December 12, 2025 at 4:27 PM
🔬 We’re watching the science at #SABCS25. Komen Scholar Susan Domchek, M.D., is excited about the WISDOM trial using genetics & polygenic risk scores to personalize screening. @sabcs.bsky.social
📖 Read more: https://www.komen.org/blog/sabcs-watch-2025/
📖 Read more: https://www.komen.org/blog/sabcs-watch-2025/
🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social
December 12, 2025 at 3:27 PM
🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social
🎉 Congrats to Komen grantees Armando Giuliano MD and Nolan Priedigkeit MD for receiving awards at this year’s @sabcs.bsky.social! #SABCS25 👏👏
December 11, 2025 at 7:07 PM
🎉 Congrats to Komen grantees Armando Giuliano MD and Nolan Priedigkeit MD for receiving awards at this year’s @sabcs.bsky.social! #SABCS25 👏👏
📢 We’re at #SABCS25! Stop by our booth in the Patient Advocacy Pavilion in the @sabcs.bsky.social Exhibition Hall! We’d love to talk to you about Komen’s mission including patient navigation, policy, research-support, education, and more!
December 11, 2025 at 6:45 PM
📢 We’re at #SABCS25! Stop by our booth in the Patient Advocacy Pavilion in the @sabcs.bsky.social Exhibition Hall! We’d love to talk to you about Komen’s mission including patient navigation, policy, research-support, education, and more!
Komen Scholar and Advocates in Science Steering Committee member Barbara Segarra-Vazquez highlights how advocates can drive meaningful change across research in the Partnership for Change session at #SABCS25. @sabcs.bsky.social
December 11, 2025 at 6:38 PM
Komen Scholar and Advocates in Science Steering Committee member Barbara Segarra-Vazquez highlights how advocates can drive meaningful change across research in the Partnership for Change session at #SABCS25. @sabcs.bsky.social
Komen grantee David Cescon discusses exciting advances in liquid biopsy tests for early breast cancer presented at #SABCS25. @sabcs.bsky.social
December 11, 2025 at 6:36 PM
Komen grantee David Cescon discusses exciting advances in liquid biopsy tests for early breast cancer presented at #SABCS25. @sabcs.bsky.social
Komen Scholar Reshma Jagsi M.D., D. Phil. highlighted research at #SABCS25 that could reduce the burden of treatment, like fewer lymph node surgeries & radiation that boosts the immune system.
📖 See what’s ahead and what we’re excited to learn about @sabcs.bsky.social here: https://bit.ly/4pWBEqa
📖 See what’s ahead and what we’re excited to learn about @sabcs.bsky.social here: https://bit.ly/4pWBEqa
December 11, 2025 at 2:47 PM
Komen Scholar Reshma Jagsi M.D., D. Phil. highlighted research at #SABCS25 that could reduce the burden of treatment, like fewer lymph node surgeries & radiation that boosts the immune system.
📖 See what’s ahead and what we’re excited to learn about @sabcs.bsky.social here: https://bit.ly/4pWBEqa
📖 See what’s ahead and what we’re excited to learn about @sabcs.bsky.social here: https://bit.ly/4pWBEqa
👏Komen honored our new early-career grantees during a celebration at #SABCS25. We are so proud to support the next generation of breast cancer leaders, investing in a talented workforce for years to come! 🎉
Learn more: https://bit.ly/49prhq1 @sabcs.bsky.social
Learn more: https://bit.ly/49prhq1 @sabcs.bsky.social
December 11, 2025 at 1:40 AM
👏Komen honored our new early-career grantees during a celebration at #SABCS25. We are so proud to support the next generation of breast cancer leaders, investing in a talented workforce for years to come! 🎉
Learn more: https://bit.ly/49prhq1 @sabcs.bsky.social
Learn more: https://bit.ly/49prhq1 @sabcs.bsky.social
Komen Scholar, Dr. Sunil Badve, presented how immune cells in residual tumors vary by breast cancer subtype in the ECOG-ACRIN EA1131 trial at #SABCS25. @sabcs.bsky.social
December 11, 2025 at 1:38 AM
Komen Scholar, Dr. Sunil Badve, presented how immune cells in residual tumors vary by breast cancer subtype in the ECOG-ACRIN EA1131 trial at #SABCS25. @sabcs.bsky.social
Another DESTINY-Breast09 update from Mothaffar Rimawi MD at #SABCS25: in HER2+ advanced breast cancer, first-line T-DXd + pertuzumab kept pain and daily functioning similar to standard THP, with more stomach issues but fewer skin and swelling symptoms 🩺📈 @sabcs.bsky.social
December 10, 2025 at 8:08 PM
Another DESTINY-Breast09 update from Mothaffar Rimawi MD at #SABCS25: in HER2+ advanced breast cancer, first-line T-DXd + pertuzumab kept pain and daily functioning similar to standard THP, with more stomach issues but fewer skin and swelling symptoms 🩺📈 @sabcs.bsky.social
🩺🧬 Shanu Modi, MD shared DESTINY-Breast11 patient-reported outcomes: In high-risk HER2+ early breast cancer, T-DXd–based pre-surgery therapy helped more patients keep up physical functioning & daily activities vs ddAC-THP, with overall manageable side effects #SABCS25
December 10, 2025 at 8:08 PM
🩺🧬 Shanu Modi, MD shared DESTINY-Breast11 patient-reported outcomes: In high-risk HER2+ early breast cancer, T-DXd–based pre-surgery therapy helped more patients keep up physical functioning & daily activities vs ddAC-THP, with overall manageable side effects #SABCS25
At #SABCS25, Kevin Punie MD presented on ASCENT-03 patient-reported outcomes: In untreated advanced TNBC not eligible for immunotherapy, sacituzumab govitecan helped patients maintain physical activity and overall well-being better than chemo @sabcs.bsky.social
December 10, 2025 at 8:07 PM
At #SABCS25, Kevin Punie MD presented on ASCENT-03 patient-reported outcomes: In untreated advanced TNBC not eligible for immunotherapy, sacituzumab govitecan helped patients maintain physical activity and overall well-being better than chemo @sabcs.bsky.social
At #SABCS25, Jean Wright MD presented results from RadComp: In locally advanced breast cancer, proton radiation therapy gave lower average doses to the heart than photon RT. 💓 At 6 months, heart-related quality of life looked similar overall, with fatigue back to baseline @sabcs.bsky.social
December 10, 2025 at 8:05 PM
At #SABCS25, Jean Wright MD presented results from RadComp: In locally advanced breast cancer, proton radiation therapy gave lower average doses to the heart than photon RT. 💓 At 6 months, heart-related quality of life looked similar overall, with fatigue back to baseline @sabcs.bsky.social
At #SABCS25, Dr. Curigliano shared DESTINY-Breast11 data in high-risk HER2+ early breast cancer: T-DXd–based neoadjuvant regimens showed a more favorable safety profile, with fewer serious toxicities compared with ddAC-THP, while keeping side effects manageable 🩺🧬 @sabcs.bsky.social
December 10, 2025 at 8:05 PM
At #SABCS25, Dr. Curigliano shared DESTINY-Breast11 data in high-risk HER2+ early breast cancer: T-DXd–based neoadjuvant regimens showed a more favorable safety profile, with fewer serious toxicities compared with ddAC-THP, while keeping side effects manageable 🩺🧬 @sabcs.bsky.social
💡 Komen Scholar Ben Park MD shares some hot topics at #SABCS25, including blood tests (liquid biopsies) that could transform how we detect and track #breastcancer.
📖 Read more about what we're watching @sabcs.bsky.social here: https://www.komen.org/blog/sabcs-watch-2025/
📖 Read more about what we're watching @sabcs.bsky.social here: https://www.komen.org/blog/sabcs-watch-2025/
December 10, 2025 at 4:15 PM
💡 Komen Scholar Ben Park MD shares some hot topics at #SABCS25, including blood tests (liquid biopsies) that could transform how we detect and track #breastcancer.
📖 Read more about what we're watching @sabcs.bsky.social here: https://www.komen.org/blog/sabcs-watch-2025/
📖 Read more about what we're watching @sabcs.bsky.social here: https://www.komen.org/blog/sabcs-watch-2025/
We’re tracking the biggest updates from #SABCS25, from liquid biopsies to genetics-guided screening🧬
#Breastcancer experts & MD’s: Ben Park, Reshma Jagsi & Susan Domchek shared what they’re watching & why it matters for patients in our blog: https://www.komen.org/blog/sabcs-watch-2025/ 💬
#Breastcancer experts & MD’s: Ben Park, Reshma Jagsi & Susan Domchek shared what they’re watching & why it matters for patients in our blog: https://www.komen.org/blog/sabcs-watch-2025/ 💬
December 9, 2025 at 3:19 PM
We’re tracking the biggest updates from #SABCS25, from liquid biopsies to genetics-guided screening🧬
#Breastcancer experts & MD’s: Ben Park, Reshma Jagsi & Susan Domchek shared what they’re watching & why it matters for patients in our blog: https://www.komen.org/blog/sabcs-watch-2025/ 💬
#Breastcancer experts & MD’s: Ben Park, Reshma Jagsi & Susan Domchek shared what they’re watching & why it matters for patients in our blog: https://www.komen.org/blog/sabcs-watch-2025/ 💬
Breast cancer screening and early detection play an important role in your health. Screening tests can help find breast cancer at an early stage when the chances of survival are highest.
Learn more about cancer screening: https://bit.ly/48RfhN7
Learn more about cancer screening: https://bit.ly/48RfhN7
December 5, 2025 at 3:49 PM
Breast cancer screening and early detection play an important role in your health. Screening tests can help find breast cancer at an early stage when the chances of survival are highest.
Learn more about cancer screening: https://bit.ly/48RfhN7
Learn more about cancer screening: https://bit.ly/48RfhN7
The fight against breast cancer matters. That’s why we are committed to transparency and accountability in everything we do.
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
November 23, 2025 at 6:22 PM
The fight against breast cancer matters. That’s why we are committed to transparency and accountability in everything we do.
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE
Breast cancer is emerging as a global health crisis, yet with support from Komen, a groundbreaking tool called the Breast Cancer Care Quality Index is providing countries a roadmap to improve breast cancer care & save lives, regardless of the resources they have.
Learn more: https://bit.ly/3X34dG8
Learn more: https://bit.ly/3X34dG8
November 18, 2025 at 6:10 PM
Breast cancer is emerging as a global health crisis, yet with support from Komen, a groundbreaking tool called the Breast Cancer Care Quality Index is providing countries a roadmap to improve breast cancer care & save lives, regardless of the resources they have.
Learn more: https://bit.ly/3X34dG8
Learn more: https://bit.ly/3X34dG8
Drumroll please! 🥁
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
November 11, 2025 at 4:11 PM
Drumroll please! 🥁
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll.
And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!
🌍🔬 At ESMO 2025, breast cancer news went off:
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
November 5, 2025 at 5:14 PM
🌍🔬 At ESMO 2025, breast cancer news went off:
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat
📍Chemo-free options for HER2+
📍Improved options in TNBC
📍Keeping cancer recurrence at bay
📍New options for metastatic ER+ BC
Read the highlights in our blog: https://bit.ly/4hHohat